Leqvio’s launch remains sluggish and tislelizumab looks even more like a dead end in the US.
Novo Nordisk delays the full US launch of its obesity drug again, as Lilly breathes down its neck.
Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.
A second year of pandemic investments helped big pharma’s combined R&D bill surge above $100bn for the first time.
But pressure is on the shingles vaccine as the consumer spin-off approaches.
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.